Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension
2019-004131-24Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan 75 mg with Placebo (2 arms). Primary endpoint: Change from baseline to Week 28 in exercise capacity. Started May 2020; status: terminated.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2019-004131-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004131-24.